Posted in | Automation Simulation

ABB Provides Power Factor Correction to Wellington Cable Car with PCS100 RPC

This video reveals how the PCS100 RPC (reactive power conditioner), available from ABB, improves the power quality of the Wellington cable car system in New Zealand. The system reduces the risk of resonance problems, prevents costly outcomes due to poor factor or harmonics, ensures correct functioning of rectifier loads by fixing voltage unbalance, and lowers maintenance costs. The PCS100 RPC is ideal for enhancing commercial and industrial electrical installations across different industries such as the public transport industry, providing power and productivity for a better world.

Run Time – 3:22min

Helping to improve the power quality for Wellington's cable car system

Other Videos by this Supplier

ABB’s PCS100 AVC Reduces Production Downtime at Takanini Facility

ABB’s PCS100 AVC Reduces Production Downtime at Takanini Facility
PCS100 UPS-I from ABB Improves Power Protection for Thomas & Betts Data Centers

PCS100 UPS-I from ABB Improves Power Protection for Thomas & Betts Data Centers
ABB’s PCS100 UPS-I System Provides Continuous Power Supply to Modern Industrial Processes

ABB’s PCS100 UPS-I System Provides Continuous Power Supply to Modern Industrial Processes
ABB’s PCS100 MV UPS Provides Complete Power Protection

ABB’s PCS100 MV UPS Provides Complete Power Protection
PCS100 RPC from ABB Provides Seamless Reactive Power Correction

PCS100 RPC from ABB Provides Seamless Reactive Power Correction
Solving Power Quality Problems with ABB’s Power Protection Systems

Solving Power Quality Problems with ABB’s Power Protection Systems

Tell Us What You Think

Do you have a review, update or anything you would like to add to this video content?

Leave your feedback
(Logout)
Your comment type
Submit

Robotics Videos by Subject Matter

What Big Pharma Isn’t Telling You About AI Labs

What Big Pharma Isn’t Telling You About AI Labs

How AI and robotics are reshaping pharmaceutical R&D—from automated labs and in silico drug design to the growing tensions around secrecy, transparency, and equitable access in healthcare innovation.

Thought Leaders

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback